Purchase this article with an account.
Bradley ONeill, Amar Shah, Joseph M Coney; Resolution of Vitreomacular Traction Using Jetrea and its Potential Role in Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2014;55(13):294.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and efficacy of intravitreal injection of Jetrea in patients diagnosed with symptomatic vitreomacular traction (VMT) and its potential role in treatment of diabetic macular edema (DME).
An 8-month retrospective chart analysis was conducted on 24 patients with symptomatic VMT who received intravitreal injection of Jetrea 125μg using standard sterile pars plana injection technique. Each patient underwent OCT imaging before treatment. Visual acuity was measured and dilated fundus exam was performed 1 week and 1 month after injection. The primary endpoint was resolution of VMT at 1 month. Secondary end points included need for surgical intervention, continued presence of macular hole, decrease in macular hole size, and change in VMT thickness.
Overall, 12 of 24 eyes in patients aged 53-94 years old (mean 71.90 years old) treated with Jetrea had complete resolution of VMT within 1 month after injection. Fifty percent of patients showed an improvement of best-corrected visual acuity. Nine eyes had macular holes, pre-injection sizes ranged from 90μm - 326μm (mean 171.78 μm); 7 holes closed after Jetrea injection. Five patients had an epiretinal membrane before injection; of those, only 1 eye resolved with treatment. Of the nine diabetic eyes treated, 4 experienced VMT resolution. Three eyes were noted to have concomitant DME; 1 of which had marked improvement of DME in addition to complete resolution of VMT.
Intravitreal injection of Jetrea successfully resolved vitreomacular traction in half of those treated. Use of Jetrea in treatment of concurrent diabetic macular edema may be a potential area of interest for future studies.
This PDF is available to Subscribers Only